The CCNL2 Knockout HeLa Polyclonal Cells are a heterogeneous CRISPR/Cas9-edited polyclonal knockout cell population designed for functional studies of cyclin L2. This product disrupts the CCNL2 gene locus in a pool of HeLa cells, generating a mixed population with diverse loss-of-function mutations, offering a robust model for studying gene function without clonal isolation. The polyclonal format mitigates clonal artifacts and provides a representative knockout background for bulk biochemical and phenotypic assays.
The host cell line, HeLa, is a widely characterized human cervical adenocarcinoma line harboring integrated HPV-18 sequences. The viral E6 and E7 oncoproteins inactivate the tumor suppressors p53 and Rb, respectively, creating a genetically permissive background for cancer and molecular biology research. These cells are routinely used to investigate oncogenic signaling, apoptosis, and gene regulation in a cancer context.
Cyclin L2, encoded by CCNL2, functions as a regulatory subunit of CDK11 to form an active kinase complex that phosphorylates SR proteins, including SRSF1 and SRSF3. This phosphorylation modulates the activity of splicing factors, thereby influencing alternative pre-mRNA splicing, transcriptional elongation, and apoptosis. The CCNL2-CDK11 complex directly phosphorylates the C-terminal domain (CTD) of RNA polymerase II and targets spliceosome components such as SF3B1. Upstream, transcription factors like SP1 and NF-??B regulate CCNL2 expression. Downstream, altered splicing of targets like BCL2L1 yields isoforms that determine apoptotic outcome. Thus, cyclin L2 sits at a nexus connecting transcription, splicing, and cell death programs.
In the HeLa cervical cancer background, disruption of CCNL2 enables interrogation of tumor-relevant alternative splicing programs and CDK11-dependent signaling. Given that HeLa cells exhibit dysregulated splicing and apoptosis, the knockout model is particularly valuable for dissecting how cyclin L2 contributes to the malignant phenotype, including aberrant splicing of oncogenes and tumor suppressors. Researchers can explore synthetic lethal interactions or test splicing-modulating therapies in a well-established cancer cell context.
Typical applications include mechanistic studies of alternative splicing, CDK11 signaling cascade analysis, and apoptosis regulation using assays such as western blotting for phospho-SR proteins, RT-qPCR for splicing isoforms, co-immunoprecipitation of CDK11 complexes, and RNA-seq-based transcriptome-wide splicing analysis. Functional genomics screens and drug target validation for splicing-related therapies are readily performed. Additionally, immunofluorescence localization and flow cytometric cell cycle or apoptosis assays (e.g., Annexin V) can characterize phenotypic consequences. For additional information or technical inquiries, please contact Ascent Research.
